X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This financing will enable MinervaX to progress its novel GBS vaccine GBS-NN/NN2, towards Phase III clinical trials in 2024. The Company is currently progressing two Phase II clinical trials in 470 pregnant persons across Denmark, United Kingdom, Uganda and South Africa.
Lead Product(s): GBS-NN,Aluminum
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN/NN2
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: EQT Life Sciences
Deal Size: $56.8 million Upfront Cash: Undisclosed
Deal Type: Financing October 11, 2023
Details:
GBS-NN/NN2 is a novel innovative, adjuvanted protein Vaccine which are based on traditional capsular polysaccharide (CPS) conjugate technology and investigated for the treatment of Group B Streptococcus.
Lead Product(s): GBS-NN,GBS/NN2
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN/NN2
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: European and Developing Countries Clinical Trials Partnership
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
The process is designed to facilitate the development of investigational treatment GBS-NN/NN2, that demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.
Lead Product(s): GBS-NN/NN2
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN/NN2
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
The GBS-NN/NN2 vaccine consists of two fusion proteins consisting of either AlpCN and RibN (GBS-NN) or Alp1N and Alp2/3N (GBS-NN2), formulated with AlOH adjuvant.
Lead Product(s): GBS-NN/NN2
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN/NN2
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: REPAIR Impact Fund
Deal Size: $23.4 million Upfront Cash: Undisclosed
Deal Type: Financing December 15, 2022
Details:
Group B Streptococcal vaccine based on traditional capsular polysaccharide (CPS) conjugate technology consists of two fusion proteins consisting of either AlpCN and RibN (GBS-NN) or Alp1N and Alp2/3N (GBS-NN2), formulated with AlOH adjuvant.
Lead Product(s): GBS-NN
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.
Lead Product(s): GBS-NN
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $57.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
